MedTrace Logo

A Double Blinded Study to Examine the Effect of Alpha Agonist Ointment on Fecal Incontinence in Patients With Idiopathic Fecal Incontinence

NCT01421823 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2013-12-12

No results posted yet for this study

Summary

The purpose of this study is to assess the effect and safety of alpha agonist ointment on fecal incontinence severity in patients with idiopathic fecal incontinence.

Conditions

  • Idiopathic Fecal Incontinence

Interventions

DRUG

alpha agonist ointment

2 weeks local treatment with alpha agonist ointment

DRUG

Placebo

2 weeks local treatment with placebo ointment

Sponsors & Collaborators

  • RDD Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Yehiel Ziv, MD · RDD Pharma Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-04-30

Countries

  • Israel

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01421823 on ClinicalTrials.gov